VTVT vTv Therapeutics

vTv Therapeutics to Present at Two Upcoming Annual Investor Conferences

HIGH POINT, N.C.--(BUSINESS WIRE)--

vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, among other therapeutic areas, today announced that company management will present a corporate overview at two upcoming investor conferences.

Presentation Details:

ROTH Capital Partners 29th Annual Growth Stock Conference

  • Location: Dana Point, California
  • Presentation Date: Tuesday, March 14, 2017
  • Presentation Time: 7:30 am PT

Needham & Co. 16th Annual Healthcare Conference

  • Location: New York, New York
  • Presentation Date: Tuesday, April 4, 2017
  • Presentation Time: 4:20 pm ET

Live webcasts of the presentations can be accessed on the News & Events section of the website. The webcasts will be archived for 30 days following the presentations on the Company’s website at www.vtvtherapeutics.com.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

EN
10/03/2017

Underlying

VTVTvTv Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on vTv Therapeutics

 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics to Participate in Upcoming Investor Conferences

vTv Therapeutics to Participate in Upcoming Investor Conferences HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDate: Thursday, February 26, 2026Time: 11:20 AM ETFormat: Presentat...

February 13, 2026 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. ...

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737 Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment immediately upon execution of the amended license agreement HIGH POINT, N.C., Feb. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adj...

February 2, 2026 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinica...

vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration with M42’s Insights Research Organization & Solutions (IROS), a leading United Arab Emirates (UAE)-based contract resea...

December 18, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Prov...

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026  $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041 HIGH POINT, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliati...

November 6, 2025 1 EN
 PRESS RELEASE
Free
VTVT vTv Therapeutic...

vTv Therapeutics Announces New Appointments to its Scientific Advisory...

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board (SAB). The SAB, composed of internationally recognize...

October 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch